Importantly, for the 55 patients who experienced tumor progression on anti–PD-1 monotherapy, the median survival (OS2) was 11.6 months for those who continued ICI postprogression (n = 38), with 18 patients (51%) being alive at the last follow-up. This evidence concerns the gene PDCD1 and neoplasm.